Zevalin In-111 is a targeted radioimmunotherapy drug used in the treatment of certain types of non-Hodgkin’s lymphoma. This medication combines a monoclonal antibody with a radioactive isotope to specifically target and destroy cancer cells while minimizing damage to healthy tissues.

Zevalin In-111 works by attaching to a protein called CD20, which is found on the surface of B-cells, a type of white blood cell that can become cancerous in lymphoma. Once the drug binds to the CD20 protein, the radioactive isotope delivers radiation directly to the cancer cells, causing them to die.

This treatment is typically used in patients with relapsed or refractory non-Hodgkin’s lymphoma who have not responded to other therapies. Zevalin In-111 is administered as a single infusion, usually in an outpatient setting. Patients may experience side effects such as low blood cell counts, fatigue, and nausea, but these are usually temporary and can be managed with supportive care.

It is important for patients to discuss their medical history and any current medications with their healthcare provider before starting Zevalin In-111 treatment. Regular monitoring and follow-up appointments will be necessary to assess the response to therapy and manage any potential side effects.

Overall, Zevalin In-111 offers a targeted and effective treatment option for patients with non-Hodgkin’s lymphoma, providing hope for improved outcomes and quality of life. As with any medication, it is important to follow your healthcare provider’s instructions and communicate any concerns or questions throughout the treatment process.